{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:23:07Z","timestamp":1792786987906,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"ResoRecherche"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      Anti\u2010tumor necrosis factor (\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      )\u2010\u03b1 agents may induce skin reactions, in particular in patients with inflammatory bowel diseases (\n                      <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>\n                      ). The objective of this study was to determine the efficacy of ustekinumab in these patients.\n                      <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>\n                      patients facing therapeutic issues because of cutaneous reactions or tolerance issues, consequently treated with ustekinumab in our department, were included. Retrospective review of case records and clinical photographs was carried out. Twenty\u2010six patients were included. Twenty\u2010three patients were treated for Crohn's disease and three for ulcerative colitis. Fourteen patients presented psoriasiform lesions, nine eczematiform lesions, four anaphylactoid reactions, two alopecia areata\u2010like lesions, one injection\u2010site reaction, one cutaneous polyarteritis nodosa and five other skin reactions. Most of them resolved under ustekinumab. In detail, eczematiform lesions completely resolved in all cases, psoriasiform lesions completely resolved in 12 cases (85.7%) and had partial response in two cases (14.3%). Two cases of alopecia areata showed complete response (complete hair regrowth). Fourteen patients showed complete digestive response, 10 patients partial digestive response (seven of which needed\n                      <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>\n                      treatment optimization) and only two failure. In conclusion, ustekinumab is a drug of choice in patients with\n                      <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>\n                      who cannot tolerate\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      blockers.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1346-8138.14816","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T08:15:36Z","timestamp":1551341736000},"page":"322-327","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Ustekinumab for skin reactions associated with anti\u2010tumor necrosis factor\u2010\u03b1 agents in patients with inflammatory bowel diseases: A single\u2010center retrospective study"],"prefix":"10.1111","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-4589","authenticated-orcid":false,"given":"Khaled","family":"Ezzedine","sequence":"first","affiliation":[{"name":"Department of Dermatology Henri Mondor University Hospital Creteil France"},{"name":"EA 7379 EpiDermE (Epidemiology in Dermatology and Thrapeutics Evaluation) UPEC\u2010University Paris\u2010Est Cr\u00e9teil Creteil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Visseaux","sequence":"additional","affiliation":[{"name":"Department of Dermatology Courlancy Clinic Rheims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cadiot","sequence":"additional","affiliation":[{"name":"Department of Gastro\u2010Enterology Reims University Hospital Rheims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedia","family":"Brixi","sequence":"additional","affiliation":[{"name":"Department of Gastro\u2010Enterology Reims University Hospital Rheims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bernard","sequence":"additional","affiliation":[{"name":"Department of Dermatology Courlancy Clinic Rheims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Reguiai","sequence":"additional","affiliation":[{"name":"Department of Dermatology Courlancy Clinic Rheims France"},{"name":"ResoRecherche Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12491"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21233"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1724"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.163642"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.01.009"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.205"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.07.022"},{"issue":"1","key":"e_1_2_7_9_1","first-page":"3","article-title":"Management of inflammatory bowel disease with infliximab and other anti\u2010tumor necrosis factor alpha therapies","volume":"24","author":"Magro F","year":"2010","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"issue":"20","key":"e_1_2_7_10_1","first-page":"2831","article-title":"Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab","volume":"17","author":"Andrisani G","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000339864"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1094179"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13499"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2011.04.003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.06.005"},{"issue":"2","key":"e_1_2_7_17_1","first-page":"e1","article-title":"Subcutaneous ustekinumab provides clinical benefit for two\u2010thirds of patients with crohn's disease refractory to anti\u2013tumor necrosis factor agents","volume":"14","author":"Wils P","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3315\/jdcr.2015.1207"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13352"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302853"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09329.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0729"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12802"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.755957"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2011.11.004"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.005"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20153084"},{"issue":"6","key":"e_1_2_7_28_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1684\/ejd.2013.2221","article-title":"Alopecia areata developing during ustekinumab therapy: report of two cases","volume":"23","author":"Tauber M","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"7","key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D34G31C0TM","article-title":"Letter: alopecia areata during ustekinumab administration: co\u2010existence or an adverse reaction?","volume":"18","author":"Verros C","year":"2012","journal-title":"Dermatol Online J"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3315\/jdcr.2010.1041"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.874737"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01967.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1027167"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.14816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.14816","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:36:04Z","timestamp":1694342164000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.14816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/1346-8138.14816"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.14816","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"2018-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}